This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Gambi, F. Articles by Ferro, F. M. Search for Related Content PubMed PubMed Citation Articles by Gambi, F. Articles by Ferro, F. M. Social Bookmarking                   What's this?

Mirtazapine treatment of Generalized Anxiety Disorder: a fixed dose, open label study

Department of Oncology and Neurosciences, Institute of Psychiatry, University ‘G. D’Annunzio’ of Chieti, Chieti, Italy, fgambi{at}unich.it

Domenico De Berardis

Department of Oncology and Neurosciences, Institute of Psychiatry, University ‘G. D’Annunzio’ of Chieti, Chieti, Italy

Daniela Campanella

Department of Oncology and Neurosciences, Institute of Psychiatry, University ‘G. D’Annunzio’ of Chieti, Chieti, Italy

Alessandro Carano

Department of Oncology and Neurosciences, Institute of Psychiatry, University ‘G. D’Annunzio’ of Chieti, Chieti, Italy

Gianna Sepede

Department of Oncology and Neurosciences, Institute of Psychiatry, University ‘G. D’Annunzio’ of Chieti, Chieti, Italy

Gabriele Salini

Department of Oncology and Neurosciences, Institute of Psychiatry, University ‘G. D’Annunzio’ of Chieti, Chieti, Italy

Daniela Mezzano

Department of Oncology and Neurosciences, Institute of Psychiatry, University ‘G. D’Annunzio’ of Chieti, Chieti, Italy

Alessandra Cicconetti

Department of Oncology and Neurosciences, Institute of Psychiatry, University ‘G. D’Annunzio’ of Chieti, Chieti, Italy

Laura Penna

Department of Oncology and Neurosciences, Institute of Psychiatry, University ‘G. D’Annunzio’ of Chieti, Chieti, Italy

Rosa Maria Salerno

Department of Oncology and Neurosciences, Institute of Psychiatry, University ‘G. D’Annunzio’ of Chieti, Chieti, Italy

Filippo Maria Ferro

Department of Oncology and Neurosciences, Institute of Psychiatry, University ‘G. D’Annunzio’ of Chieti, Chieti, Italy

We investigated the efficacy of mirtazapine in the treatment of generalized anxiety disorder (GAD). Forty-four adult outpatients with GAD were treated openly with a fixed dose of mirtazapine (30mg) for 12 weeks. The primary outcome measure was the change from baseline in total score on the Hamilton Rating Scale for Anxiety (HAM-A). The Clinical Global Impression of Improvement (CGI-I) was rated at the endpoint. Patients with a reduction of 50% or more on the HAM-A total score and a CGI-I score of 1 or 2 at endpoint were considered responders to treatment; remission was defined as a HAM-A score 7. At 12 weeks, response was achieved by 79.5% of the patients (n 35) and remission by 36.4% of patients (n 16). This study supports the notion that mirtazapine is an efficacious and well tolerated treatment for GAD. Limitations of the present study must be considered and further placebo-controlled trials are needed.

Key Words: mirtazapine • generalized anxiety disorder • open label • pharmacotherapy

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. Singh, P. Ghazvini, N. Robertson, A. J. Massey, O. Kirksey, and M. S. Honeywell Sleep Disturbances in Patients With Psychiatric Illnesses Journal of Pharmacy Practice, December 1, 2006; 19(6): 369 - 378. [Abstract] [PDF]